Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan van Lunzen

Showing results (31-40 of 112) with videos related to

Pageof 12
Sort By:
AIDS Research and Therapy|July 10, 2014
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patientsClaudia Beisel, Martin Heuer, Benjamin Otto, et al.
Virology Journal|April 20, 2016
Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotypeSuvercha Bhardwaj, Fareed Ahmad, Heiner Wedemeyer, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infectionJustyna D Kowalska, Amanda Mocroft, Anders Blaxhult, et al.
Journal of the International AIDS Society|November 14, 2014
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGOJean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, et al.
BMC Public Health|April 24, 2012
Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methodsAlison Rodger, Tina Bruun, Matthew Weait, et al.
Plos One|February 6, 2014
Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in EuropeAlexander Zoufaly, Alessandro Cozzi-Lepri, Joanne Reekie, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 9, 2010
Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patientsKarin J Metzner, Pia Rauch, Patrick Braun, et al.
The Lancet. HIV|October 2, 2015
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b studyJean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 23, 2008
Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patientsClara Lehmann, Jill M Harper, Dirk Taubert, et al.
The Lancet. Infectious Diseases|October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen, Franco Maggiolo, José R Arribas, et al.
Pageof 12

Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
AIDS Research and Therapy|July 10, 2014
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patientsClaudia Beisel, Martin Heuer, Benjamin Otto, et al.
Virology Journal|April 20, 2016
Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotypeSuvercha Bhardwaj, Fareed Ahmad, Heiner Wedemeyer, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infectionJustyna D Kowalska, Amanda Mocroft, Anders Blaxhult, et al.
Journal of the International AIDS Society|November 14, 2014
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGOJean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, et al.
BMC Public Health|April 24, 2012
Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methodsAlison Rodger, Tina Bruun, Matthew Weait, et al.
Plos One|February 6, 2014
Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in EuropeAlexander Zoufaly, Alessandro Cozzi-Lepri, Joanne Reekie, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 9, 2010
Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patientsKarin J Metzner, Pia Rauch, Patrick Braun, et al.
The Lancet. HIV|October 2, 2015
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b studyJean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 23, 2008
Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patientsClara Lehmann, Jill M Harper, Dirk Taubert, et al.
The Lancet. Infectious Diseases|October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen, Franco Maggiolo, José R Arribas, et al.
Pageof 12